Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Chinese Academy of Sciences · Institute of Microbiology · +8 more institutions
Abstract
Abstract COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (M pro , also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting M pro . Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further…
Citation impact
- FWCI
- 10.66
- Percentile
- 100%
- References
- 42
Authors
16- LFLifeng FuCorresponding
Chinese Academy of Sciences, Institute of Microbiology
- FYFei Ye
Chinese Center For Disease Control and Prevention, National Institute for Viral Disease Control and Prevention
- YFYong Feng
Chinese Academy of Sciences, Institute of Microbiology, University of Chinese Academy of Sciences
- FYFeng Yu
Chinese Academy of Sciences, Shanghai Advanced Research Institute
- QWQisheng Wang
Chinese Academy of Sciences, Shanghai Advanced Research Institute
Topics & keywords
- Boceprevir
- Virology
- Protease
- Vero cell
- Coronavirus
- Telaprevir
- Virus
- Biology
- Good health and well-being
Funding
- NNNational Natural Science Foundation of ChinaAwards: 2016YFD0500300, 21807109
- CAChinese Academy of SciencesAwards: 2018ZX10733403, XDB29010202
- NSNational Science and Technology Major ProjectAward: 2018ZX10733403
- NKNational Key Research and Development Program of ChinaAwards: 2016YFD0500300, 2016YFE0205800
- IOInstitute of Microbiology, Chinese Academy of Sciences